A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 80; no. 3; pp. 339 - 340
• Main Authors: Alrifai, Doraid, Popat, Sanjay, Ahmed, Merina, Gonzalez, David, Nicholson, Andrew G, Parcq, John du, Benepal, Tim
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ireland Ltd 01.06.2013; Elsevier
• Subjects: Activating mutations; Aged; ALK; Biological and medical sciences; BRAF; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Squamous Cell - diagnosis; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - pathology; Coexistence; Coexisting; Dermatology; EML4-ALK; Hematology, Oncology and Palliative Medicine; Humans; Lung cancer; Male; Medical sciences; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Mutation; Non-small cell lung cancer; Pneumology; Proto-Oncogene Proteins B-raf - genetics; Pulmonary/Respiratory; Receptor Protein-Tyrosine Kinases - genetics; Squamous cell carcinoma; Transcriptional Activation; Tumors; Tumors of the respiratory system and mediastinum; Tumors of the skin and soft tissue. Premalignant lesions; ALK; EML4-ALK; Squamous cell carcinoma; Activating mutations; Lung cancer; Non-small cell lung cancer; Coexisting; BRAF; Coexistence; Lung disease; Skin disease; Basal cell carcinoma; Respiratory disease; Lung; Malignant tumor; non-small cell lung carcinoma; Case study; Bronchus disease; Mutation; Cancer
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2013.02.002

Abstract The management of non-small cell lung cancer has significantly changed over the past few years through greater understanding of tumour biology. The identification of activating mutations has led to the development of targeted agents. Coexisting mutations in non-small cell lung cancer is uncommon, particularly in squamous cell carcinoma. Our case represents a late gentleman with squamous cell carcinoma of the lung with both a BRAF mutation and ALK rearrangement prior to treatment.